Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Levodopa-Induced dyskinesia in Latin America: Prevalence and associated clinical factors in the LARGE-PD cohort.

Journal of Parkinson's disease·2026

Same author

Systematic review of movement disorders mislabeled as functional: when incongruence misleads.

Journal of neurology·2026

Same author

International Parkinson and Movement Disorder Society Clinical Outcome Assessments are Available in REDCap.

Movement disorders : official journal of the Movement Disorder Society·2026

Same author

Update on Medical Treatments for Essential Tremor: An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review.

Movement disorders : official journal of the Movement Disorder Society·2026

Same author

The Role of Basal Ganglia Theta Oscillations in Predicting the Onset of Levodopa-Induced Dyskinesias.

Movement disorders : official journal of the Movement Disorder Society·2025

Same author

Comment to "Further Considerations on the Research of Parkinson's Disease-Related Chronic Pain".

Movement disorders clinical practice·2025

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Pregabalin-induced parkinsonism: a case report.

Santiago Perez Lloret¹, Mariela Amaya, Marcelo Merello

¹Movement Disorders Section, Neuroscience Department, Institute for Neurological Research Raul Carrea FLENI, Montañeses 2325, Buenos Aires, Argentina. spl@etymos-med.com.ar

Clinical Neuropharmacology

|December 3, 2009

Summary

Pregabalin (PGB), a medication for nerve pain and seizures, can cause parkinsonism. A patient developed severe parkinsonian symptoms after starting PGB, which resolved after discontinuing the drug.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Experiment Videos

Last Updated: Jun 18, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Area of Science:

Neurology
Pharmacology

Background:

Pregabalin (PGB) is an L-type, voltage-dependent, calcium-channel blocker used for neuropathic pain and seizures.
Diabetic sensory-motor polyneuropathy is a common indication for PGB treatment.

Observation:

A 64-year-old woman developed parkinsonism, including axial symptoms, tremor, bradykinesia, and rigidity, after initiating PGB.
The patient's symptoms were bilateral, symmetric, and consistent with drug-induced parkinsonism.

Findings:

PGB withdrawal led to significant improvement in parkinsonian symptoms, with the Unified Parkinson's Disease Rating Scale motor score decreasing from 27 to 0.
This case highlights a potential adverse effect of PGB, distinct from previously reported tremors.

Implications:

Clinicians should be vigilant for parkinsonism in patients treated with PGB.
This report suggests PGB may induce parkinsonism, necessitating careful patient monitoring.